Disclosed is a prevention and treatment of pancreatitis including administering a naphthoquinone-based compound, a pharmaceutically acceptable salt, a prodrug, a solvate, or an isomer thereof. Particularly, the naphthoquinone-based compounds β-lapachone and dunnione can reduce the pancreatic weight/body weight ratio, which is increased by pancreatitis； reduce the increased activities of digestive enzymes (amylase and lipase)； reduce the expressions of cytokines (IL-1β (interleukin-1β and MCP-1)； reduce or inhibit the inflammation, edema, and cell necrosis of the pancreatic tissues； and inhibit the lung damage caused by pancreatitis. Therefore, the naphthoquinone-based compound, pharmaceutically acceptable salt, prodrug, solvate, or isomer thereof can be effectively used for the prevention and treatment of pancreatitis mediated diseases.
